The efficacy of the GLP1 receptor agonists exenatide, liraglutide, lixisenatide, and semaglutide for PD treatment is being evaluated in clinical trials (ClinicalTrials.gov Identifiers: NCT04305002; NCT02953665; NCT03439943; NCT03659682). This evidence concerns the gene GLP1R and Parkinson disease.